CD86 and neoplasm: We found no differences in the abundance of CD11b— dendritic cells (DCs) in TDLNs harvested at days 17–18 post-tumor challenge (Figure 6C, Kruskal–Wallis test, KW = 1.96, p = 0.582); although therapy did increase CD86 expression on DCs from both OB-RES and DIO mice (Figure 6D, Kruskal–Wallis test, KW = 11.50, p = 0.009).